Vaxxinova is excited to announce the successful acquisition of the Avishieldยฎ poultry vaccine range from Dechra and the Dechra poultry vaccine research and development team based in Zagreb, Croatia.
This acquisition marks a significant milestone in our growth, enabling us to:
- ย Offer a complete portfolio of live vaccines against Infectious Bronchitis (IB), Gumboro Disease (IBD) and Newcastle Disease (ND)
- ย Have direct access to the European poultry vaccines market and strengthen our presence in the international markets
- ย Continue the development of the corresponding R&D pipeline, by the Zagreb R&D team
Victor van Solinge, Chief Executive Officer of Vaxxinova, remarked โThe addition of the Avishieldยฎ portfolio significantly strengthens our position in the poultry vaccine market and complements our existing VAXXONยฎ range. We are excited to welcome the R&D team in Zagreb, whose expertise will be instrumental to further extend our portfolio. This acquisition underlines our long-term commitment to the poultry industry.โ
Dechra and Vaxxinova agreed on a smooth transition period, securing business continuity.
Weโre excited about the opportunities this brings to our partners, customers, and the broader animal health community.